ABPI Logo
  • Developing medicines
    • Responding to COVID-19
    • Clinical trials and research
    • Building a thriving environment for medicine discovery
    • UK-EU Future Relationship
    • Life Sciences Industrial Strategy
    • ABPI Medical Representatives Exam
  • Accessing medicines
    • How medicines are priced in the UK
    • Working with the NHS
    • Supply chain
    • Antimicrobial resistance (AMR)
    • Vaccines
    • What is the NICE Methods Review?
    • Rare diseases: Facing three challenges
  • Our ethics
    • ABPI Code of Practice
    • Disclosure UK
    • Appropriate prescribing
    • Patient & public involvement
  • Member representation
    • Events
    • Full membership
    • Working with our members​
    • ABPI Members List
    • Membership benefits
  • Who We Are
  • Media
  • Publications
  • Facts and Figures
  • Contact Us
MY ABPI LOGIN
 
  • The Association of the British Pharmaceutical Industry
  • Accessing medicines
  • How medicines are priced in the UK
  • How are new medicines developed?

How are new medicines developed?

Medicines and vaccines are some of the most important ways we have to fight disease on a global scale and keep people fit and healthy.

Globally the pharmaceutical industry is working on researching and developing more than 7,000 potential new medicines and vaccines to treat and sometimes cure conditions like cancers, Alzheimer’s, diabetes and very rare genetic diseases.

Since the 1960’s medicines and vaccines have helped increase life expectancy by more than ten years, turned HIV AIDs from a death sentence to a manageable disease and made strides in eradicating malaria. We’re now seeing exciting new personalised therapies treating and curing more diseases including cancers.

Every year our companies put hundreds of billions of pounds into new research and development – more than any other industry.

Despite many failures, some of these medicines and vaccines will help to transform the lives of NHS patients in the future.

It’s a high-risk industry, but one which helps save and prolong the lives of millions of people around the world every day.

 

 

 

 

How medicines are priced in the UK

  • How are new medicines developed?
  • How are medicines priced?
  • The Voluntary Scheme on branded medicines
  • What is the life cycle of a medicine?
  • What is the NICE Methods Review?
  • Improving access to medicine in the UK
  • The future of medicine
  • Supporting innovative medicines funding in Scotland
  • What was the PPRS?

ABPI

The Association of the British Pharmaceutical Industry is a company limited by guarantee registered in England and Wales 
(registered number 09826787) and its registered office is at 7th Floor Southside,105 Victoria Street, London, SW1E 6QT.
Telephone +44 (0) 207 9303477

© ABPI 2021
  • Twitter Logo
  • LinkedIn
  • YouTube Logo

Devolved Nations

  • Cymru Wales
  • Northern Ireland
  • Scotland

Quick Links

  • ABPI Exam
  • Disclosure UK
  • Frequently Asked Questions
  • Careers
  • Schools
  • Acronym buster

Website Info

  • Terms and conditions
  • Accessibility
  • Cookie Policy

Prescription Medicines Code of Practice Authority (PMCPA)

The Prescription Medicines Code of Practice Authority (PMCPA) was established by The Association of the British Pharmaceutical Industry to operate the ABPI Code of Practice for the Pharmaceutical Industry independently of the ABPI. The PMCPA is a division of ABPI which is a company registered in England and Wales (registered number 09826787) with its registered office at 7th Floor, Southside, 105 Victoria Street, London SW1E 6QT.

Office of Health Economics (OHE)

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 7th Floor Southside, 105 Victoria Street, London, SW1E 6QT. OHE provides independent research, advisory and consultancy services on policy implications and economic issues within the pharmaceutical, health care and biotechnology sectors.